These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9001836)

  • 41. Pharmacokinetics and pharmacodynamics of mibefradil in hypertensive patients with varying degrees of renal insufficiency.
    Welker HA; Weidekamm E; Houwing N; de Chatel R
    Pharmacology; 1998 Jun; 56(6):297-307. PubMed ID: 9654216
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group.
    Viskoper RJ; Bernink PJ; Schelling A; Ribeiro AB; Kantola IM; Wilkins MR; Kobrin I
    J Hum Hypertens; 1997 Jun; 11(6):387-93. PubMed ID: 9249234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
    Massie BM; Lacourcière Y; Viskoper R; Woittiez A; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):27C-33C. PubMed ID: 9286851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mibefradil withdrawn from the market.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998; 32(7-8):841. PubMed ID: 9681103
    [No Abstract]   [Full Text] [Related]  

  • 45. Good news for experimental concept but bad news for clinically effective therapy.
    Reimer KA; Califf RM
    Circulation; 1999 Jan; 99(2):198-200. PubMed ID: 9892582
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial.
    Tzivoni D; Kadr H; Braat S; Rutsch W; Ramires JA; Kobrin I
    Circulation; 1997 Oct; 96(8):2557-64. PubMed ID: 9355894
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
    Welker HA
    J Pharm Pharmacol; 1998 Sep; 50(9):983-7. PubMed ID: 9811158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.
    Massie BM; Chrysant SG; Jain A; Weir M; Weiss R; Korrin I
    Clin Cardiol; 1997 Jun; 20(6):562-8. PubMed ID: 9181268
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The interaction of the calcium antagonist RO 40-5967 with digoxin.
    Siepmann M; Kleinbloesem C; Kirch W
    Br J Clin Pharmacol; 1995 May; 39(5):491-6. PubMed ID: 7669484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension.
    Schmitt R; Kleinbloesem CH; Belz GG; Schroeter V; Feifel U; Pozenel H; Kirch W; Halabi A; Woittiez AJ; Welker HA
    Clin Pharmacol Ther; 1992 Sep; 52(3):314-23. PubMed ID: 1526090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Current therapy of coronary heart disease. Conservative measures].
    Stephan S
    Internist (Berl); 1998 Sep; 39(9):1001-2. PubMed ID: 9788131
    [No Abstract]   [Full Text] [Related]  

  • 52. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.
    Mulder P; Richard V; Compagnon P; Henry JP; Lallemand F; Clozel JP; Koen R; Macé B; Thuillez C
    J Am Coll Cardiol; 1997 Feb; 29(2):416-21. PubMed ID: 9014998
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease.
    Pordy R; Woittiez A
    Int J Clin Pharmacol Res; 1998; 18(3):105-8. PubMed ID: 9825266
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Short-term hemodynamic effects of mibefradil in dogs with chronic heart failure: comparison with diltiazem.
    Shimoyama H; Sabbah HN; Tanimura M; Borzak S; Goldstein S
    J Pharmacol Exp Ther; 1998 May; 285(2):746-52. PubMed ID: 9580622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate.
    Cleophas TJ; van der Sluijs J; van der Vring JA; Daniëls MC; Holwerda KJ; Withagen AJ; Schelling A; Hendriks MG; Zwinderman AH
    J Clin Pharmacol; 1999 Jul; 39(7):738-46. PubMed ID: 10392329
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Induction of bradycardia by mibefradil in antihypertensive combination therapy].
    Wagner J; Ritz E
    Dtsch Med Wochenschr; 1998 Apr; 123(17):547. PubMed ID: 9601479
    [No Abstract]   [Full Text] [Related]  

  • 57. Serious interaction between mibefradil and tacrolimus.
    Krähenbühl S; Menafoglio A; Giostra E; Gallino A
    Transplantation; 1998 Oct; 66(8):1113-5. PubMed ID: 9808502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
    Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
    Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
    [No Abstract]   [Full Text] [Related]  

  • 59. Mibefradil pharmacokinetic and pharmacodynamic population analysis.
    Welker HA; Banken L
    Int J Clin Pharmacol Res; 1998; 18(2):63-71. PubMed ID: 9675623
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
    Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
    J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.